$3,150,000 of AMGEN INC lobbying was just disclosed, from Q3 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment S.3345, PBM Price Transparency and Accountability Act HR 6166, Lowering Drug Costs for American Families Act S 3019 - No Big Blockbuster Bailouts Act S 3349 PBM Disclosure Act HR 4317 PBM Reform Act Issues related to Public law 117-1769 Inflation Reduction Act HR 1672 Maintaining Investments in New Innovation Act (MINI) HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 PL 119-75 Consolidated Appropriations Act of 2026 HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act HR 10628/ S 5571 Biosimilars Access and Affordability Act S 5244 Sustain 340B Act HR 9599 Secure 340B Act Issues related to corporate and international tax Public Law 115-97, Tax Cuts and Jobs Act Public Law 119-21, One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) Issues related to Puerto Rico Issues related to OECD negotiations on the taxation of global income Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act H.R.5526 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act HR 7391 Community Health Center Drug Pricing Protection Act HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act (Reconciliation 2.0) S 3014 Ensuring Timely Access to Generics Act of 2025 S 2355 Patients Deserve Price Tags Act HR 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 HR 8800 National Defense Authorization Act for Fiscal year 2027 HR 9102 BINSA Bill COINS Act, enacted within P.L. 119-60 National Defense Authorization Act for Fiscal Year 2026 S 1414 Expedited Access to Biosimilars Act HR 10628/ S 5571 Biosimilars Access and Affordability Act S 5244 Sustain 340B Act HR 9599 Secure 340B Act HR 5509/ S 2903 Safe Step Act Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025 Issues related to tariffs Issues related to trade agreements S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025"
You can find more data on corporate lobbying on Quiver Quantitative.
AMGN Congressional Stock Trading
Members of Congress have traded $AMGN stock 5 times in the past 6 months. Of those trades, 2 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $AMGN stock by members of Congress over the last 6 months:
- REPRESENTATIVE DAVID TAYLOR has traded it 4 times. They made 2 purchases worth up to $30,000 on 09/22, 06/05 and 2 sales worth up to $30,000 on 08/26.
- SENATOR SHELDON WHITEHOUSE sold up to $15,000 on 08/12.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
AMGN Insider Trading Activity
AMGN insiders have traded $AMGN stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $AMGN stock by insiders over the last 6 months:
- NANCY A. GRYGIEL (SVP & CCO) has made 0 purchases and 3 sales selling 4,207 shares for an estimated $1,594,866.
- DEREK MILLER (SVP, Human Resources) has made 0 purchases and 2 sales selling 3,890 shares for an estimated $1,565,897.
- RACHNA KHOSLA (SVP, Business Development) has made 0 purchases and 2 sales selling 3,252 shares for an estimated $1,346,498.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
AMGN Hedge Fund Activity
We have seen 1,417 institutional investors add shares of AMGN stock to their portfolio, and 1,346 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 15,034,038 shares (+inf%) to their portfolio in Q2 2026, for an estimated $5,444,125,840
- INVESCO LTD. added 11,748,721 shares (+257.0%) to their portfolio in Q2 2026, for an estimated $4,254,446,848
- CAPITAL INTERNATIONAL INVESTORS removed 5,453,497 shares (-76.6%) from their portfolio in Q2 2026, for an estimated $1,974,820,333
- JPMORGAN CHASE & CO added 3,588,484 shares (+inf%) to their portfolio in Q2 2026, for an estimated $1,299,461,826
- WELLINGTON MANAGEMENT GROUP LLP added 2,514,254 shares (+1102.7%) to their portfolio in Q2 2026, for an estimated $910,461,658
- BLACKROCK, INC. added 2,261,544 shares (+4.8%) to their portfolio in Q2 2026, for an estimated $818,950,313
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC added 2,260,652 shares (+17.7%) to their portfolio in Q2 2026, for an estimated $818,627,302
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
AMGN Price Targets
Multiple analysts have issued price targets for $AMGN recently. We have seen 6 analysts offer price targets for $AMGN in the last 6 months, with a median target of $340.0.
Here are some recent targets:
- Terence Flynn from Morgan Stanley set a target price of $333.0 on 07/08/2026
- Gregory Renza from Truist Securities set a target price of $340.0 on 07/07/2026
- Carter Gould from Cantor Fitzgerald set a target price of $350.0 on 07/06/2026
- Salim Syed from Mizuho set a target price of $303.0 on 06/16/2026
- David Amsellem from Piper Sandler set a target price of $427.0 on 05/14/2026
- Vamil Divan from Guggenheim set a target price of $340.0 on 05/04/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
